EU/3/11/890

About

On 5 August 2011, orphan designation (EU/3/11/890) was granted by the European Commission to Kowa Pharmaceutical Europe Co. Ltd, United Kingdom, for peretinoin for the treatment of hepatocellular carcinoma.

The sponsorship was transferred to Kowa Pharmaceutical Europe GmbH, Germany, in July 2018.

Key facts

Active substance
Peretinoin
Disease / condition
Treatment of hepatocellular carcinoma
Date of decision
05/08/2011
Outcome
Positive
Orphan decision number
EU/3/11/890

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Kowa Pharmaceutical Europe GmbH
Görreshof 151
53347 Alfter
Germany
Tel. +49 2287 1002776
E-mail: orphandrugs@proppert-solutions.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating